© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
The story of Kanamycin B Sulfate traces back to a period when the race to tame infectious diseases shaped medical practice. Back in the late 1950s, researchers in Japan isolated kanamycin from Streptomyces kanamyceticus, setting off a new era in antibiotic therapy. As time moved on, chemists realized this natural mixture gave rise to several related compounds—kanamycin A, B, and C—each bringing its own attributes to the table. Kanamycin B was not the star of the clinical world, but wound up important in laboratories and industry, especially as the field of molecular genetics took off. Experience in the lab taught many of us that Kanamycin B plays a foundational role as a selection agent in bacterial culture, making it a quiet partner in experiments that push medicine and biotechnology forward.
Ask anyone in a molecular biology lab about selection markers, and kanamycin often comes up, even if not always in reference to Kanamycin B. As a salt—specifically the sulfate—this compound dissolves in water with ease, making everyday lab work more predictable. Despite carrying the name of a classic antibiotic, Kanamycin B hangs back from clinical limelight and instead finds a regular place in research settings. Its attributes align it more with academic inquiry and industrial biosystems than hospital drug cabinets. This difference matters, since every product that spots a niche and does one job very well ends up becoming vital somewhere in the research and development pipeline.
Flip open a technical sheet and the basic facts start to paint a picture. Kanamycin B Sulfate appears as a white to off-white powder, turning clear in solution and keeping stability for weeks when stored properly. With a molecular weight hovering in the 500s and polar groups dotting both ends, the compound spreads easily in aqueous buffers. It resists breakdown at room temperature and tolerates autoclaving, a benefit for those preparing sterile solutions for microbial selection. Chemically, kanamycin B belongs to the aminoglycoside family—most folks remember its structure for the telltale amino sugars tethered to a central ring, packed with nitrogens and hydroxyls that love to latch onto bacterial ribosomal RNA. These structural elements sit at the heart of what lets kanamycin B shut down protein synthesis in susceptible cells.
Open any bottle of Kanamycin B Sulfate and you’ll spot clear labeling about purity, water content, and storage temperature. Concentration guidelines matter most. At the bench, most users work with the 10–50 mg/mL range, and sources warn about proper handling, since aminoglycosides, even in small quantities, pose health risks if inhaled or ingested. Labels don’t just serve compliance—they ensure the accuracy and repeatability modern science demands. Attention to technical details reduces experimental noise and supports reliability across projects and labs worldwide.
Pulling Kanamycin B from a soup of fermentation broth is equal parts art and science. Grown in tightly controlled fermenters, Streptomyces kanamyceticus churns out this antibiotic and its siblings after careful optimization of nutrients and growth phases. Extraction dances between acid and base steps, coaxing kanamycin B away from other byproducts. Crude extracts undergo repeated crystallization and chromatography until the powder meets purity standards. Every stage—from microbial health to solvent choice—shapes the final product. Having seen the headaches that come from shortcuts in purification, I know firsthand how important these technical details become for experimental success.
Kanamycin B shows its true utility not so much on its own, but as a foundation for chemical transformation. Chemists often tweak its structure: acylation or alkylation of its amino groups changes binding affinity, producing derivatives for research into ribosomal inhibition or resistance mechanisms. Such changes yield analogs used to map bacterial protein synthesis or develop enzyme-linked detection systems in bioassays. The same molecular features that frustrate pathogenic bacteria also let scientists turn Kanamycin B into a probe, a marker, or a regulatory agent in synthetic biology. Scientists have used these modifications both to shed light on how aminoglycosides interact with nucleic acids and to design smarter selections for genetically engineered strains.
Kanamycin B belongs to a crowded family, each member with synonyms and multiple trade names reflecting source or pharmaceutical history. While recognized mostly under its common name and “Kanamycin B Monosulfate” or simply “Kan B”, ambiguity can spark confusion in fast-moving projects. In my experience, being precise about compound identity avoids both wasted resources and misinterpretation of results, especially when global teams or suppliers join a common project. Naming conventions are sometimes dismissed as a minor detail, but a missed detail here can unravel months of effort.
Treating any aminoglycoside calls for respect and control. Even compounds used mostly outside clinical medicine carry significant toxicity risks. Daily lab routines build in safety habits: donning gloves, using exhaust hoods, and never opening the bottle near food or drink. Kanamycin B demands the same operational care as more familiar microbiological agents. On top of that, institutions rely on well-documented MSDS sheets and train staff to respond quickly to spills or exposure. Regulatory frameworks may not spell out stringent guidelines for every use, but cutting corners on safety always catches up in the end. Experience reminds me that solid habits shield against both mistakes and long-term health impacts—lessons worth passing to every new generation in the lab.
Kanamycin B Sulfate rarely makes headlines outside focused scientific circles. Yet, its versatility shines across applications: from driving recombinant selection in bacteria, to acting as a marker in plant transformation, to supporting basic research in protein synthesis. Its effectiveness at knocking down susceptible strains turns it into a backbone of molecular cloning efforts. Recent trends push its use toward industrial fermentations, too, since robust selection agents underpin stable expression systems in scaled-up bioprocesses. The growing push for sustainable biofactories in pharmaceuticals, enzymes, and green chemistry circles back to reliable, effective markers like Kanamycin B. In some research, this compound fills a gap where resistance to other drugs builds up too easily, underscoring the value in having many tools in the antibiotic toolbox.
Research with Kanamycin B stands as an example of how old molecules remain relevant by adapting to new problems. Early on, the main focus was therapeutic application, but time taught us that lab-scale innovation boosts productivity and discovery. Scientists now use its structure to map resistance genes, study ribosomal methylation, and design next-generation selection systems for CRISPR-engineered organisms. The steady rise in multi-drug resistance worldwide even spurred reevaluation of aminoglycosides, seeking ways to tweak the molecules for renewed clinical relevance. Intellectual property questions, access to pure starting material, and environmental persistence emerged as roadblocks, but creative problem-solving keeps the story alive. Sharing lessons across chemical, microbiological, and ecological specialties helps keep progress grounded in real-world constraints.
No account of Kanamycin B would be complete without a close look at toxicity. The broader aminoglycoside family bears a reputation for ototoxicity—damage to hearing—that shadows every new application. Studies in animals and cell systems continue to mark thresholds for safe use and monitor for side effects, even at concentrations far below what clinical patients received decades ago. Use in the lab often escapes media scrutiny, but solid risk assessments keep scientists from repeating old mistakes. Modern biosafety standards ask for documented waste disposal, tracking of accidental releases, and clear reporting chains for exposure. Given what’s known about aminoglycoside persistence and off-target effects, rigorous handling remains the best safeguard against both personal and environmental harm.
Looking forward, Kanamycin B may never return to medical glory, yet its technical utility grows every year. Demand for genetic tools and robust research standards keeps this compound relevant even as new antibiotics or gene editors rise to fame. Advances in synthetic biology and biotechnology drive efforts to develop kanamycin variants, tailor resistance genes with reduced cross-resistance, and shrink the ecological burden of antibiotic selection in bioproduction. As open science spreads, global access to pure Kanamycin B supports teams in low-resource settings, leveling the playing field for innovation. Greater understanding of molecular structure, resistance, and safe handling will shape the next round of breakthroughs—reminding us that even old molecules can power new discoveries, so long as we treat both chemical and human risks with equal care.
Kanamycin B Sulfate is one of those antibiotics that doesn’t draw much attention outside labs and hospitals, but it holds a crucial place in both medicine and scientific research. The story traces back to the discovery of kanamycin-producing Streptomyces bacteria, where years of careful observation led to the isolation of different forms. The B variant, often seen as a sibling to kanamycin A, comes into play under specific circumstances, especially where resistance to more common antibiotics turns into a real problem.
Doctors sometimes deal with infections that just won’t budge, caused by bacteria resistant to more mainstream drugs. These tough bugs open the door for older antibiotics to make a comeback. Kanamycin B Sulfate steps in for severe cases, usually in settings where other treatments have lost their punch. It tackles tuberculosis strains that ignore first-line drugs and fights bacteria responsible for difficult urinary tract and abdominal infections. This drug isn’t handed out casually. Healthcare providers evaluate kidney health and hearing, since aminoglycosides bring risks beyond getting rid of germs. The trade-off makes sense only for the most stubborn infections.
Medical applications make headlines, but Kanamycin B Sulfate has quietly boosted genetic research for decades. Scientists rely on it to select and grow bacteria carrying engineered DNA. In a standard experiment, researchers insert new genes along with a gene for kanamycin resistance. Only bacteria picking up the resistance grow in media laced with Kanamycin B Sulfate, making sorting easier and saving weeks of trial and error. Many breakthroughs in biotechnology—like insulin production, vaccine development, or the study of disease genes—use this selection method. Labs trust Kanamycin B Sulfate because of its reliability and track record in generating clean, sharp results.
While Kanamycin B Sulfate remains a powerful tool, increasing antibiotic resistance tests our ability to keep these drugs viable. I’ve watched hospitals juggle limited choices, trying to avoid overusing broad-spectrum antibiotics. Each time bacteria adapt, future infections get tougher to treat. The cycle pushes medical professionals to combine old and new solutions, invest in stewardship, and rethink prescription habits. Clinical staff now track resistance patterns closely and work to limit unnecessary use, buying precious time for these drugs to stay useful.
In research, purity and accurate dosing are paramount, but access can hinge on cost and international rules. Academic labs, especially those with tight budgets, sometimes have trouble obtaining high-grade material. Shared protocols and open-source methods help, letting scientists compare results and troubleshoot more efficiently. Finding ways to support these collaborative efforts makes the science stronger while reducing misuse.
Responsibility doesn’t land on any one person or sector. Healthcare teams, regulatory agencies, researchers, and pharmaceutical companies each shape the way Kanamycin B Sulfate gets used. Training nurses to watch for side effects, encouraging physicians to consider alternatives, and fostering clear communication in research settings all make a difference. Clear labeling, transparent sourcing, and ongoing education reflect a commitment to health and trust that patients and scientists deserve. Balancing access with mindful use keeps options on the table for both the present and future.
Kanamycin B Sulfate isn’t some everyday cabinet item. This is an antibiotic most labs know as crucial for genetic selection, especially when working with bacteria that carry specific resistance genes. In my years supporting microbiology research teams, I saw more experiments fail from overlooked storage issues than from lab mishaps. The roots of that problem often come down to temperature, humidity, and how people underestimate what a room’s microclimate can do to a powder or solution.
Keep Kanamycin B Sulfate at 2 to 8 degrees Celsius. That’s a standard refrigerator — not the freezer. If you’ve worked in microbiology or chemistry for a while, you know that keeping things in the right cold environment keeps out trouble. Above 8°C, the potency drops faster, which means your results get inconsistent or your cultures just… stop growing. The science here links back to how proteins and other molecules break down over time if warmth speeds up their movement. A fridge limits that, so you get the full strength every time.
It’s easy to ignore, but I’ve seen Kanamycin B Sulfate turn slightly yellow after too many days of sunlight peeking through a window or left open on a benchtop while students work with agar plates. Direct light can cause chemical changes over time, which might not show up in the results for weeks. Always keep it in a tightly capped, amber vial or use a brown glass bottle. Moisture matters too. Even with the best intentions, humidity in the air will get into a bottle that’s left open. Clumping, caking, and potential microbial contamination follow. Keep silica gel packs in the storage area and always seal bottles quickly after each use.
Nobody likes tossing out expensive antibiotics. Good habits keep waste down. Label everything clearly, whether it’s the powder form or a ready-to-use solution. Date every container, and don’t trust your memory. Rotate stocks and always use old supplies first. If you see a change in color or notice unusual smells, discard the material. Pretty obvious to experienced techs, but new lab staff sometimes miss these simple steps and lose weeks of work.
In shared labs, labeling fights and open containers drive most Kanamycin B Sulfate issues. Personal stories pile up about grad students needing high antibiotic plates for E. coli selection, only to realize the last batch lost its punch. The answer comes down to respectful shared space: sign every vial, and communicate about who mixed what and when. Bring in an inventory logbook. I’ve even found small thermometers in fridges go a long way for early alerts when things are off.
For field labs in places with power cuts, portable coolers with ice packs save a whole week’s work if the main fridge goes down. Also, ordering in smaller amounts or making fresh solutions weekly keeps the material potent.
Bottom line, Kanamycin B Sulfate serves as a foundation in countless research projects and medical production processes. How you store it — and how much attention you pay to the basics of temperature, light, humidity, and labeling — shapes the results of every single experiment it touches.
Molecular weight might sound like a line from a chemistry textbook, but it plays a role in how drugs perform and how safely we can use them. This value comes from adding up the atomic weights of every atom in the molecule. Knowing this number shapes how pharmacists dose Kanamycin B Sulfate and make decisions about mixing or compounding medications. Round numbers in science rarely tell the full story, but for Kanamycin B Sulfate, you’ll see 582.58 g/mol for Kanamycin B itself and roughly 729.71 g/mol for the sulfate salt form most often used in clinical settings.
If you’ve ever worked in a hospital pharmacy or watched a doctor order an antibiotic infusion for a patient with kidney trouble, you know details matter. A small dosing error can trigger side effects or leave an infection under-treated. The difference between Kanamycin B and its sulfate form, for example, could add up if the wrong value ends up on a pharmacy label. The extra weight from the sulfate group increases the total mass per mole, making precision in calculation absolutely necessary.
I once spent an afternoon untangling a medication error on a pediatric unit, and the root cause traced back to confusion over which molecular weight a dosing guide used. Standardizing information for everyone on the care team can stop mistakes long before they hurt someone who’s vulnerable.
The pharmaceutical world lives and dies by its numbers. Regulators like the FDA and EMA won’t let a drug leave the plant unless the batch records show every box checked, including that the product matches its known molecular weight. Labs run purity tests by confirming the actual mass of a dose compares to quality guidelines. If the weight drifts, contamination or degradation could be a factor, and the batch gets flagged.
I've talked to quality assurance professionals who treat this step as sacred. Every time a new lot arrives, it gets tested against literature values, such as 729.71 g/mol for Kanamycin B Sulfate. A difference signals a problem, and nobody ignores even a tenth of a gram.
Researchers depend on these numbers from the start. A chemist developing a new antibiotic-based therapy needs the correct molecular weight to design experiments, calculate concentrations, and build a model predicting how a drug behaves in the bloodstream. Even slight mistakes send hundreds of thousands of dollars’ worth of research down the wrong path. That puts pressure on suppliers and educators to keep formulas, datasheets, and product specs current and accurate.
If you regularly work with compounds like Kanamycin B Sulfate, double-checking the number becomes second nature. Standardized digital resources, lab information systems, and clear labeling go a long way toward reducing confusion. Cross-training staff ensures more eyes notice oddities. And if a number on a bottle doesn’t agree with your reference, trust the instinct to check before moving ahead.
Getting the molecular weight correct provides a foundation for safe patient care, reliable science, and consistent quality. It’s a detail with wide-reaching impact, all the way from the manufacturing line to the bedside. The small print on a drug label sometimes tells a bigger story than we might expect.
Antibiotics show up in every cell culture lab I know. Contamination costs time, money, and patience. Kanamycin B Sulfate hits gram-negative bacteria hard and knocks out some gram-positives too. Lots of scientists—including me—reach for it when other antibiotics stall or act weak. Kanamycin B comes up as an option since it blocks protein production in bacteria, throwing a wrench in any unwanted microbial plans. At the end of a long week cleaning out flasks, that’s something to value.
Lab folks argue about the best antibiotic almost like sports teams. Penicillin-streptomycin covers a broad range, but resistance always creeps in. Gentamicin works, yet some microbes slip through. Kanamycin B Sulfate works on bacteria that outsmart ampicillin or gentamicin. That quality saves batches sometimes. I’ve had plasmid amplifications that tanked on ampicillin but thrived on kanamycin. Choice matters depending on what you grow and what you need.
Safety and toxicity matter to everyone handling live cultures. Kanamycin B Sulfate can put stress on eukaryotic cells, not just bacteria. Stick with low concentrations—usually around 50 μg/ml in common cell culture work—to dodge cell death. I’ve seen cell lines shrivel or grow sluggish if the dose creeps up. Set up a control plate and test your cell line before diving in; rescued experiments later won’t bring back lost days.
Antibiotic resistance shapes modern cell culture, especially in genetic selection. Kanamycin B Sulfate supports screening of kanamycin-resistance genes in bacterial transformations. Mammalian and insect cell lines may use geneticin or hygromycin for selection, but bacterial work with kanamycin-resistant vectors relies on this antibiotic. Most protocols haven’t shifted away from it because resistance frequencies stay manageable and results come through reliably.
Fungal spores and mycoplasma come up as silent troublemakers in cell culture. Kanamycin B Sulfate doesn’t touch them. I learned the hard way: a bottle of kanamycin didn’t stop a slow, nasty mycoplasma outbreak. If mold or mycoplasma lurk, Kanamycin B Sulfate offers almost no protection. Relying only on one antibiotic often encourages stealthy, resistant microbes. Rotating antibiotics or using a cocktail with antifungals covers your bases better and keeps cultures healthy.
Studies back up personal observations. Published work from journals like "Applied and Environmental Microbiology" shows kanamycin selection keeps bacterial contamination low in typical lab strains. Dosage and timing change results—using too much slows eukaryotic growth, too little risks breakthrough infections. Talking with university core facility techs confirms that balance matters; every new cell line benefits from a gentle test run with fresh antibiotic stocks.
Building a backup plan starts before the culture goes bad. Use certified antibiotic stocks. Always filter sterilize antibiotic solutions, and store vials cold and away from light. Keep an eye on expiration dates. If cultures develop odd colors, fuzzy colonies, or stop growing, swap out media and test for contamination right away rather than blaming the antibiotic. Combining Kanamycin B Sulfate with other antibiotics or antifungals cuts infection chances and reduces resistant survivor strains.
Kanamycin B Sulfate slots into cell culture routines where resistance patterns fit and toxicity stays low. Good technique—sterile work, clean stocks, regular monitoring—makes any antibiotic perform better. Choosing the right antibiotic takes asking honest questions about what’s growing, what might intrude, and how cells respond. Results depend on that level of care, not just what bottle sits on the bench.
Laboratories focused on molecular biology keep certain antibiotics on standby. Kanamycin B sulfate plays a clear role when picking out bacteria with the right resistance gene. In my own projects, kanamycin opens a straightforward path to selecting transformants—when you rely on the tried and true, you spend less time re-running controls. It's worth knowing what concentration will reliably tell the imposters from the genuine colonies.
The sweet spot for kanamycin B sulfate lands at 50 micrograms per milliliter for Escherichia coli and similar bacteria. Decades of published protocols echo this. For transformations with standard plasmid vectors, that number gets results. You'll see white, round patches blooming on plates, and you won’t waste time squinting at lawns of non-selectable background. This number doesn’t come from nowhere—studies align on growth inhibition in wild-type E. coli starting around 25 μg/mL, and by 50 μg/mL, sensitive strains give up the fight.
Some stubborn species—like Pseudomonas or environmental isolates—shrug off lower doses or seem less sensitive. Here, researchers use concentrations up to 100 μg/mL. Checking strain and vector documentation helps keep your workflow solid. Over time, I learned not to jump to 100 μg/mL for E. coli unless you see evidence of escape mutants or naturally resistant strains.
Too little kanamycin and you risk overcrowded plates packed with non-transformants. Too high, and even resistant colonies can struggle—yield drops, growth slows, and sometimes, you see nothing. For routine cloning, wasting time on plates with the wrong dose slows projects and racks up the cost. Kanamycin itself isn’t the most expensive part of cloning work, but wasted media and lost time add up.
Manufacturers like Sigma-Aldrich and Thermo Fisher lay out similar numbers, calling for 30 to 50 μg/mL for E. coli. Peer-reviewed journals reflect this. If you look at the protocols from Cold Spring Harbor, the numbers fit. In a course I taught, we began with 50 μg/mL in both Luria-Bertani agar and broth, and fresh college students could quickly see the difference between selective and non-selective plates.
Kanamycin degrades in air or under bright lights. Plates left out too long lose their punch. Using freshly prepared antibiotic stocks (filter-sterilized, never autoclaved) keeps things consistent. If you’re using liquid selection, bacteria reach stationary phase and chew through available resources, including the antibiotic. Don’t keep cultures sitting at 37°C for days on end; subculture as soon as the log phase plateaus.
Storage and handling make a difference—store kanamycin sulfate at -20°C for long-term stability, and avoid repeated freeze-thaw cycles. Adjusting for unusual strains matters. If a mutant or environmental isolate dodges the selection, confirm gene presence by PCR or check the sequence. For highly resistant backgrounds, titrate plates with a range of concentrations—30, 50, 75, and 100 μg/mL—before settling in.
It’s tempting to save time and copy protocols, but vigilance with concentration pays off. Keep a fresh batch of plates, check batch labels, and use the right controls. If contamination issues crop up, revisit antibiotic strength and storage. Talking with colleagues, reaching into the literature, and keeping a notebook close at hand saves headaches and helps you set reliable working conditions for kanamycin B sulfate.
| Names | |
| Preferred IUPAC name | Kanamycin B sulfate |
| Other names |
Kanamycin monosulfate Kanamycin B sulfate salt KANA Kanmikin B sulfate Kanamycin sulfate |
| Pronunciation | /ˌkæn.əˈmaɪ.sɪn ˈbiː ˈsʌlf.eɪt/ |
| Identifiers | |
| CAS Number | '4697-14-7' |
| Beilstein Reference | 3854839 |
| ChEBI | CHEBI:6108 |
| ChEMBL | CHEMBL1194899 |
| ChemSpider | 20557353 |
| DrugBank | DB13404 |
| ECHA InfoCard | 100.120.446 |
| EC Number | 205-505-5 |
| Gmelin Reference | 77000 |
| KEGG | C01740 |
| MeSH | D016864 |
| PubChem CID | 44136652 |
| RTECS number | NJ3Q93V71F |
| UNII | 0B8T8Q3NW9 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C18H36N4O11·H2SO4 |
| Molar mass | 1444.6 g/mol |
| Appearance | White or almost white powder |
| Odor | Odorless |
| Solubility in water | Soluble in water |
| log P | -6.2 |
| Acidity (pKa) | 7.2 |
| Basicity (pKb) | 7.3 |
| Viscosity | Viscous liquid |
| Dipole moment | 0 D |
| Pharmacology | |
| ATC code | J01GB04 |
| Hazards | |
| Main hazards | Harmful if swallowed, inhaled, or absorbed through skin. Causes eye, skin, and respiratory tract irritation. |
| GHS labelling | GHS labelling: Hazard pictograms: GHS07; Signal word: Warning; Hazard statements: H315, H319, H335; Precautionary statements: P261, P264, P271, P280, P302+P352, P305+P351+P338 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | Hazard statements: "H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Precautionary statements: P261, P264, P271, P272, P273, P280, P302+P352, P304+P340, P305+P351+P338, P308+P313, P312, P321, P332+P313, P337+P313, P362+P364, P403+P233, P405, P501 |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| LD50 (median dose) | LD50 (median dose): Mouse (intraperitoneal): 4,000 mg/kg |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 10mg/ml |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Kanamycin A Sulfate Kanamycin Sulfate Neomycin Sulfate Gentamicin Sulfate Tobramycin Amikacin Sulfate |
